AU2020381495A1 — Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate
Assigned to Seagen Inc · Expires 2022-05-19 · 4y expired
What this patent protects
The present disclosure relates to a method for treating or ameliorating the effects of a HER2 positive breast cancer in a subject by administration of a combination of tucatinib and an anti-HER2 antibody-drug conjugate (
USPTO Abstract
The present disclosure relates to a method for treating or ameliorating the effects of a HER2 positive breast cancer in a subject by administration of a combination of tucatinib and an anti-HER2 antibody-drug conjugate (
Drugs covered by this patent
- Tukysa (tucatinib) · Seagen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.